Aug 12, 2020
QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma
Aug 12, 2020
KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors
Jun 22, 2020
Dracen announces two DRP-104 presentations at AACR
Jun 10, 2020
PharmAbcine execute an agreement with Thermo Fisher for the development and manufacturing of its next-generation immune checkpoint blockade, PMC-309 for Phase I
Jun 09, 2020
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO(TM) and KEYTRUDA® Plus Chemotherapy
Jun 05, 2020
Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference
Jun 04, 2020
Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses
Jun 04, 2020
OncoSec to Present at Virtual Summer Investor Summit
Jun 03, 2020
Online Video Education Series from SITC and PlatformQ Health to Better Equip HCPs Managing Cancer Patients Undergoing Immunotherapy
Jun 02, 2020
Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study
Jun 02, 2020
World Market for Next Generation Immune Checkpoint Inhibitors and Stimulators - Forecast and Opportunity Analysis
May 27, 2020
Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort
May 25, 2020
Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China
May 18, 2020
Innovent Biologics and MD Anderson Announce a Strategic Collaboration to Develop anti-PD-1 Therapy TYVYT® (Sintilimab Injection) in Rare Cancers
May 14, 2020
INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment
May 13, 2020
Oncolytics Biotech® to Present at the RBC Global Healthcare Conference
May 12, 2020
Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030
May 06, 2020
OncoSec's TAVO(TM) in Combination with KEYTRUDA® Demonstrated 41% Overall Response Rate and 36% Complete Response in a Late-Stage Metastatic Melanoma Study Featured in 'Clinical Cancer Research'
Apr 24, 2020
Global Immune Checkpoint Modulators Market 2020 - Current and Emerging Key Products & Players, Main Unmet Needs, R&D Challenges, Strategies & Opportunities, Clinical Development Trends
Apr 23, 2020
SITC Announces Three Recipients of the 2020 Richard V. Smalley, MD, Memorial Award and Lectureship